Gang Li

Prof. Dr. Gang Li


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YRYichang Ren
Yichang Ren
YWYuxi Wang
Yuxi Wang
GLGang Li
Gang Li
ZZZherong Zhang
Zherong Zhang
LMLingling Ma
Lingling Ma
JCJianjun Chen
Jianjun Chen

21 March 2016 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
PYPeng Yang
Peng Yang
YJYong Jian
Yong Jian
XZXue Zhou
Xue Zhou
GLGang Li
Gang Li
TDTuo Deng
Tuo Deng
ZTZhangmin Tian
Zhangmin Tian

1 September 2020 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GLGang Li
Gang Li
YWYuxi Wang
Yuxi Wang
LLLing Li
Ling Li
YRYichang Ren
Yichang Ren
XDXin Deng
Xin Deng
JCJianjun Chen
Jianjun Chen

1 March 2021 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
GLGang Li
Gang Li
WQWenqing Qi
Wenqing Qi
XLXiaoxun Li
Xiaoxun Li
JZJinwu Zhao
Jinwu Zhao
MLMeihua Luo
Meihua Luo
JCJianjun Chen
Jianjun Chen
C-Jun N-Terminal Kinases (JNKs), members of the Mitogen-Activated Protein Kinase (MAPK) signaling pathway, play a key role in the pathogenesis of many diseases including cancer, inflammation, Parkinson’s disease, Alzheimer’s disease, cardiovascular disease, obesity, and diabetes. Therefore, JNKs represent new and excellent target by therapeutic agents. Many JNK inhibitors based on different molecular scaffolds have been discovered in the past decade. However, only a few of them have advanced to clinical trials. The major obstacle for the development of JNK inhibitors as therapeutic agents is the JNKisoform selectivity. In this review, we describe the recent development of JNK inhibitors, including ATP competitive and ATP non-competitive (allosteric) inhibitors, bidentatebinding inhibitors and dual inhibitors, the challenges, and the future direction of JNK inhibitors as potential therapeutic agents.

21 November 2016 in New Journal of Chemistry
Verified
Journal Article
Closed access
PDF file
YZYong Zhan
Yong Zhan
PYPeng Yang
Peng Yang
GLGang Li
Gang Li
YZYuanyuan Zhang
Yuanyuan Zhang
YBYing Bao
Ying Bao
A novel D–π–A type triphenylamine modified benzothiazole derivative TVBT was synthesized, and it could emit strong fluorescence in solution and in the solid state. It should be noted that TVBT revealed reversible piezofluorochromic behaviors upon grinding and fuming with DCM vapor/heating treatment on account of the reversible transformation between the crystalline and amorphous states. The single crystal X-ray diffraction data revealed that the intermolecular interactions of C–H⋯N (2.54 Å, 2.68 Å), C–H⋯S (2.58 Å, 2.74 Å) and C–H⋯π (2.83 Å, 2.88 Å) would lead to the increased rigidity of the molecular skeleton, which would give rise to a loose packing motif, yielding piezofluorochromism. Interestingly, TVBT also exhibited reversible and remarkable acid/base-induced fluorescence switching properties in both solution and the solid state. In particular, the ground film of TVBT rapidly responded to TFA vapor. For example, the fluorescence gradually quenched with the increase of the concentration of TFA. When the concentration of TFA vapor was 459 ppm, the quenching efficiency reached 95.3%. In addition, the ground film of TVBT could also detect other volatile acid vapors, such as HCl and HNO3. Therefore, the ground film of TVBT could act as a fluorescence chemosensor with high performance for the naked-eye detection of volatile acid vapors by color and emission changes.

13 February 2018 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
ZYZhaozheng YANG
Zhaozheng YANG
YCYan Chen
Yan Chen
GLGang Li
Gang Li
ZTZhangmin Tian
Zhangmin Tian
LZLiang Zhao
Liang Zhao
PYPeng Yang
Peng Yang